Macrogenics (MGNX) Retained Earnings (2012 - 2026)
Macrogenics (MGNX) posted quarterly Retained Earnings of -$1.3 billion for Q1 2026, down 5.81% year-over-year from -$1.4 billion in Q1 2025, and down 2.96% quarter-over-quarter from -$1.2 billion in Q4 2025.
Analysis
Macrogenics (MGNX) Retained Earnings (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Retained Earnings for 15 consecutive years, with -$1.3 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 5.81% year-over-year to -$1.3 billion; the TTM figure through Mar 2026 stood at -$1.3 billion (down 5.81% YoY), while the FY2025 annual figure was -$1.2 billion, down 6.38% from the prior year.
- Retained Earnings slipped to -$1.3 billion in Q1 2026 per MGNX's latest filing, from -$1.2 billion in the prior quarter.
- Across five years, Retained Earnings topped out at -$1.0 billion in Q1 2022 and bottomed at -$1.3 billion in Q1 2026.
- Historically, Retained Earnings has averaged -$1.2 billion across 5 years, with a median of -$1.2 billion in 2024.
- Annual changes were most pronounced in 2022 — Retained Earnings retreated 26.4% — and 2023, when it grew 4.5%.
- Macrogenics' Retained Earnings stood at -$1.1 billion in 2022, then slipped by 0.83% to -$1.1 billion in 2023, then retreated by 6.07% to -$1.2 billion in 2024, then decreased by 6.38% to -$1.2 billion in 2025, then declined by 2.96% to -$1.3 billion in 2026.
- Business Quant data shows MGNX's Retained Earnings at -$1.3 billion in Q1 2026, -$1.2 billion in Q4 2025, and -$1.2 billion in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Macrogenics | 284.90 Mn | 171.00 Mn | - | -1.26 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.26 Bn |
| Mar 31, 2026 | -1.28 Bn |
| Dec 31, 2025 | -1.24 Bn |
| Sep 30, 2025 | -1.23 Bn |
| Jun 30, 2025 | -1.25 Bn |
| Mar 31, 2025 | -1.21 Bn |
| Dec 31, 2024 | -1.17 Bn |
| Sep 30, 2024 | -1.15 Bn |
| Jun 30, 2024 | -1.21 Bn |
| Mar 31, 2024 | -1.15 Bn |
| Dec 31, 2023 | -1.10 Bn |
| Sep 30, 2023 | -1.06 Bn |
| Jun 30, 2023 | -1.07 Bn |
| Mar 31, 2023 | -1.13 Bn |
| Dec 31, 2022 | -1.09 Bn |
| Sep 30, 2022 | -1.11 Bn |
| Jun 30, 2022 | -1.08 Bn |
| Mar 31, 2022 | -1.04 Bn |
| Dec 31, 2021 | -973.94 Mn |
| Sep 30, 2021 | -915.91 Mn |